Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Synovial 2Sarcoma 2Rhabdomyosarcoma 2Neurofibrosarcoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Fibrosarcoma 2Sarcoma, Alveolar Soft Part 1Ovarian Neoplasms 1Malignant mesenchymal tumor 1Hemangiopericytoma, Malignant 1Gastrointestinal Stromal Tumors 1

Interventions

Doxorubicin 4Ifosfamide 3Trabectedin 2perifosine 1indolepropanol phosphate 1fludarabine 1brostallicin 1X-Rays 1Watchful Waiting 1Radiotherapy, Conformal 1Radiotherapy 1Observation 1Mass Spectrometry 1Imatinib Mesylate 1Filgrastim 1Cyclophosphamide 1Crizotinib 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Sarcoma, Alveolar Soft Part × brostallicin × Clear all
NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Unknown
118 enrolled
GynecologicSarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡